BIO Calls Rebate Rule a “Significant Step Forward” for Patients

The Biotechnology Innovation Organization (BIO) this week lauded an administration proposal that would be a significant step forward in passing along  savings from drugmakers’ rebates to beneficiaries enrolled in the Medicare drug benefit program and state Medicaid drug programs. In a letter to the U.S. Department of Health and Human Services, John Murphy, BIO’s Deputy General Counsel, writes:
“We firmly believe that the rebates drugmakers provide insurers and other m